Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive August 1, 2011 Peter Houston	Google+ and Pharma Is Google+ the social media platform that pharma has been waiting for?
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool December 4, 2007 Brian Lawler	Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
Pharmaceutical Executive October 1, 2011	Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
Pharmaceutical Executive February 1, 2014 Longacre et al.	Social Media: Have We Reached The Tipping Point? For pharma marketers, the good news is recent advances in social media monitoring make it possible to listen to or engage with patients on social media websites. This month FDA released its draft guidance on the use of "Interactive Promotional Media."
CRM November 2009 Lauren McKay	Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology.
Pharmaceutical Executive December 1, 2013 Peter Young	2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.
Pharmaceutical Executive December 1, 2006 Ragnar Lofstedt	Back Page: The Post-Trust World People no longer put their faith in industry or regulators. What can we do about that? A good start would be understanding the human side of risk.
Information Today November 13, 2006 Ed Vawter	Thomson Pharma Adds 2.2 Million Chemical Structures to PubChem Database While it is exciting to see content from a major information source such as Thomson Pharma get incorporated into a freely available government-sponsored database such as PubChem, there are still drawbacks.
Chemistry World January 11, 2013 Andrew Turley	Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger.
Chemistry World December 6, 2012 Andrew Turley	Return on drug R&D dropping The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and -- on a more positive note -- there are more compounds going into late stage development.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
Pharmaceutical Executive June 1, 2006 Ron Buzzeo	Sales Management: Gifting Laws Cause Regulatory Woe New legislation forces drug companies to rethink marketing and sales initiatives.
Chemistry World September 11, 2014 Emma Stoye	Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters.
The Motley Fool September 3, 2004 Charly Travers	MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions.
Pharmaceutical Executive October 1, 2008 Patrick Clinton	Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Pharmaceutical Executive August 1, 2011 Bill Drummy	The Slow Dance Toward Obsolescence Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change?
Pharmaceutical Executive April 1, 2007 Kristin Rand	Back Page: Where are the Women? Despite efforts to increase diversity, the stark reality is that today's leading pharmaceutical companies are still run by men.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive September 1, 2008 Walter Armstrong	The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
Pharmaceutical Executive May 1, 2009 Lee Slovitt	A Day Late and a Dollar Short Pharma marketers face a crisis in digital media. But there's a way to turn it around.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
Pharmaceutical Executive April 1, 2007 Bill Trombetta	Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?
The Motley Fool July 24, 2007 Brian Lawler	Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters.
CRM August 1, 2009 Lauren McKay	The New Prescription for Pharma To address trends in the industry, pharmaceutical companies must do more with less and reshape their messages - not the easiest of tasks.
Pharmaceutical Executive August 1, 2008 Marjorie Martin	All Aboard! What's it going to take for pharma to get on board Web 2.0 and depart from the "selling and telling" approach?
Chemistry World December 8, 2011 Sarah Houlton	Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry.
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay	Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it.
Bio-IT World September 2005 Michael A. Greeley	Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets.
Pharmaceutical Executive March 1, 2007 Maraldo & Lister	Back Page: Let's Get Gutsy Pharma gets no respect from the public. But instead of complaining about it, industry should stop whining and start leading. Here's a seven-point starter kit.
Pharmaceutical Executive January 1, 2009 Stephen E. Gerard	Pharma Confidential In these tough times, how does pharma see its future? How confident are top executives in the future of the industry and their own company? Does size make a difference? Operations executives from a cross section of large, mid-tier, and specialty companies answer these questions and more.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
Pharmaceutical Executive November 1, 2006 Joanna Breitstein	Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
Pharmaceutical Executive September 1, 2011	Turning the Ins and Outs of Marketing Inside-Out Keeping your finger on the pulse of consumers leads to better, more actionable insights and better results.
Chemistry World June 6, 2013 Phillip Broadwith	Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
Chemistry World May 15, 2014 Phillip Broadwith	Lilly protests $450m Brazilian fine The Brazilian subsidiary of pharma major Eli Lilly has been ordered to pay a $450 million fine by a local court.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
Pharmaceutical Executive October 1, 2005 Christopher Lisanti	Physician Frustration Doctors have had enough. But reps can still redeem themselves. As the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.
Pharmaceutical Executive August 1, 2013 Peter Houston	The Case for Content Reaching skittish consumers through objective, story driven information is digital marketing's hottest digit. But applying this consumer phenomenon in Big Pharma presents some unique challenges.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.